Backed by M12 – Microsoft’s Venture Fund and Playground Global, 1910 Genetics will scale its AI and organic automation platforms, construct its world-class group, develop partnerships with biopharma corporations and advance its pipeline of therapeutic applications
1910 Genetics, a biotechnology firm integrating synthetic intelligence (AI), computation and organic automation to enhance drug improvement, launched on March 23, 2021 after closing its $22M Series A funding spherical. The firm’s core mission is to lower the timeline and price of drug improvement, whereas enhancing the success fee of getting medicines to sufferers. 1910 Genetics has two drug discovery engines that allow the design of each small molecule and protein therapeutics, an unmatched functionality within the AI drug discovery area. The Series A financing is co-led by M12 – Microsoft’s Venture Fund and Playground Global.
This new spherical of financing follows 1910 Genetics’ beforehand unannounced $4.1M Seed spherical, which was led by Sam Altman, CEO of OpenAI and former President of Y Combinator, with participation from FoundersX Ventures, Y Combinator, Scientia Ventures, Emles Advisors, Tuck Lye Koh of Shunwei Capital, and different notable traders.
1910 Genetics’ end-to-end expertise powers the early drug discovery course of, from novel hit discovery to hit to steer and lead optimization. With a strong mixture of biology experience, a concentrate on targets with actual illness validation and a completely built-in course of that features in-house automated moist labs, 1910 Genetics is fixing the time, value and productiveness challenges impeding the present pharmaceutical R&D mannequin. The breadth of 1910 Genetics’ built-in AI and organic automation platforms empowers the corporate to be therapeutic area-agnostic with purposes in a variety of ailments with important unmet medical wants.
“Typically, drugs have been discovered via a sequential trial-and-error process, rather than being designed by a repeatable framework that learns from data, pursues multiple paths simultaneously and, ultimately, increases the number of drugs that achieve FDA approval,” stated Dr. Jen Nwankwo, Founder and Chief Executive Officer of 1910 Genetics. “I wanted to create a biopharmaceutical company that was built from the ground up with AI, computation and biological automation rather than adding technology as a cherry on top of an archaic process. As a biologist by training, I believe that computational technologies are only impactful in drug discovery when driven by biology. This is our North Star at 1910 Genetics.”
In conserving with its mission, 1910 Genetics’ title pays homage to the yr through which Sickle Cell Disease (SCD) was first found within the U.S. by James B. Herrick. For every drug design marketing campaign, the 1910 Genetics group begins by understanding the molecular foundation of the illness to the granularity at which the world understands SCD. This understanding drives the corporate’s drug discovery engines, ELVIS™ for small molecules and ROSALYND™ for proteins, to quickly design therapeutics by integrating AI, large knowledge, cloud computing, computational chemistry, quantum simulation and organic automation.
Having confirmed its expertise towards troublesome targets in neuroscience, 1910 Genetics recognized the COVID-19 pandemic as one other alternative to display the complete functionality of its drug discovery engine to speed up small molecule drug design. 1910 Genetics efficiently deployed two of its platforms to design small molecule candidates that block SARS-CoV-2 entry into host cells. SUEDE™ screened a digital library of 1 billion small molecules in a couple of hours and recognized promising hit candidates, whereas BAGEL™ generated de novo small molecule drug candidates. After quickly manufacturing each units of molecules, 1910 Genetics examined them in-house utilizing its automated moist lab platform, which validated the efficiency of two novel candidates in blocking SARS-CoV-2 entry into mammalian cells. Dr. Nwankwo was invited by the NIH to current this speedy AI-driven drug discovery effort through the first-ever NIH SARS-CoV-2 Virtual Summit alongside distinguished leaders like Dr. Anthony Fauci in November 2020. For extra about these findings, please go to the Summit website and examine the recording.
In reference to the corporate’s Series A financing, Samir Kumar, Managing Director at M12, and Jory Bell, General Partner at Playground Global, might be becoming a member of 1910 Genetics’ Board of Directors.
“The growing number of AI and biotech companies in the market today demonstrates the promise of AI to advance the healthcare industry. After evaluating several companies in the space, we’re betting on 1910 Genetics to bring AI-designed drugs to market,” stated Mr. Kumar. “1910’s biology-first approach, combined with AI and computation, is the key to making significantly more progress toward that goal.”
“At Playground, we believe that life science is still waiting for its industrial revolution. While the semiconductor industry is known for its exponential pace of advancement, drug discovery in the biopharma sector has become slower and more expensive over time,” stated Mr. Bell. “1910 has developed a comprehensive suite of interlocking AI platforms — combined with a high throughput automated wet lab — meant to break this bottleneck and bring life-saving medicines to market faster, cheaper and more reliably.”
1910 Genetics’ AI Platforms
1910 Genetics is exclusive in its functionality to use AI to the design of each small molecule and protein therapeutics. ELVIS™ is 1910 Genetics’ small molecule drug discovery engine, which consists of three AI platforms and one organic assay platform. Beginning with the novel hit discovery stage, the corporate deploys SUEDE™, its gigascale digital screening platform, which nearly screens 14 billion molecules in lower than six hours to establish promising hit compounds. This speedy timeline and decrease value are in sharp distinction to the normal pharmaceutical course of which takes six months to finish an costly, bodily, excessive throughput screening (HTS) that delivers hit compounds with lower than a 0.01% success fee. In the hit to steer section, 1910 Genetics deploys BAGEL™, its generative chemistry platform that quickly generates de novo lead compounds utilizing a success compound as a template. Importantly, BAGEL™ is ready to lower the normal hit to steer course of from as much as 24 months to 2 months.
1910 Genetics additionally believes that whereas efficiency is vital, a drug candidate must steadiness efficiency with a number of bodily properties that finally decide the perfect absorption, distribution, metabolism, excretion and toxicity (ADMET) profile for a drug. As such, proper from the start of novel hit discovery, and particularly within the lead optimization section, the corporate deploys CANDID™, its bodily property prediction platform for multi-parameter optimization. These three AI platforms are built-in through cloud computing with 1910 Genetics’ in-house organic automation moist lab platform, which conducts in vitro biochemical and cell-based assays on the drug candidates and returns the moist lab knowledge in a suggestions loop to the AI platforms, whereas constructing a differentiated and proprietary knowledge set. For protein design, 1910 Genetics is creating ROSALYND™, its AI-driven discovery engine, which aspires to offer a sooner, extra reasonably priced and extra correct various to X-ray crystallography for the aim of 3D protein construction refinement, prediction and de novo protein therapeutics design.
About 1910 Genetics
1910 Genetics integrates AI, computation and organic automation to speed up the design of small molecule and protein therapeutics. The firm blends AI-driven drug design with organic moist lab automation to extend productiveness and reduce failure charges throughout the pharmaceutical R&D course of. Using its multi-platform drug discovery engines – ELVIS™ and ROSALYND™- 1910 Genetics can generate extra novel drug candidates, shorten the timeline, lower operational prices and improve the likelihood of success in comparison with conventional pharmaceutical strategies. 1910 Genetics’ therapeutic area-agnostic, end-to-end expertise powers the complete size of early drug discovery – from novel hit discovery to hit to steer, and lead optimization. 1910 Genetics is presently making use of its expertise to drug discovery applications in a number of areas together with, however not restricted to, neuroscience, infectious illness, immunology and oncology. The firm was based in 2018 and is headquartered in Cambridge, Massachusetts. To study extra about 1910 Genetics, go to www.1910genetics.com.